Watch Capital Markets Day 2024 presentation here
We are a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials, providing end-to-end early clinical development services to our broad and longstanding client base of biopharma companies
Yamin 'Mo' Khan
CEO at hVIVO
"The results of H1 2024 reflect the hard work, flexibility and commitment of the team. During a period of significant activity including the build-out and move to a new facility, we have not only materially increased our revenue but also further improved our margins. The concurrent running of three different facilities helped to boost our revenues for H1 2024, creating an expected H1 2024 weighting.
We have full visibility over our expected 2024 revenues and continue to deliver on our sustainable growth strategy. The orderbook remains strong in spite of record revenue delivery in H1 2024. The recent Omicron characterisation study contract and the award of our largest field study to date are two key sales highlights for H1 2024. In addition, the current sales pipeline includes several advanced stage opportunities that we expect to convert in the coming months.
The outlook for hVIVO is positive as we welcomed our first volunteers into our new facility at Canary Wharf – the world’s largest human challenge trial unit. I believe we have laid the foundations for strong performance in the months and years ahead."
H1 2024 Revenue
H1 2024 EBITDA Margin
Cash 30 June 2024
2024 Revenue Guidance
Strong market dynamics
Scalable infrastructure
Trusted partner
Orderbook growth
Our values
We are a diverse group of individuals working for one team to achieve common goals. Each one of us plays a crucial role in the team's success. We are committed to each other and the team. We learn from our failures together and celebrate our successes together. Diversity and inclusion are at the core of our organisation, and we consider our clients’ success as our own.
We are dedicated to the growth of our colleagues, customers and shareholders. We are committed to our personal growth and the development of our colleagues. We aim to grow our client base and the value of their products. We will repay the trust of our shareholders in achieving greater returns on their investment. We will achieve this by creating a culture of intellectual freedom across the organisation.
We take personal ownership of our actions and always act in ways that builds trust and respect with all our stakeholders. We pride ourselves in maintaining the welfare and the rights of all individuals and ensuring the best outcomes for our volunteers and patients. We are honest, have strong moral and ethical principles and are reliable and consistent in our delivery.
We are pioneering in our approach, always curious. We use our unique scientific expertise to guide our client’s towards successful outcomes. We embrace new opportunities and rise to new challenges. Our agility allows us to redefine our markets and be highly responsive to our clients’ requirements.
